- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Placebo, Volrustomig
- Other · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more
Location Directory
Clinical trials in Birmingham, Alabama
This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1973
Shown on this page
12
Current sort
Recently updated
Location scope
Birmingham, AL
Filters apply within this location only.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Showing 445–456 of 1,973 matching trials in Birmingham, AL.
Indexed local directory records.
Institutions in Birmingham
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Stored official records
Open in full search- Conditions
- Obesity
- Interventions
- Placebo, survodutide
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more
- Conditions
- Adenocarcinoma, Adenocarcinoma of Colon, Colo-rectal Cancer, Colon Cancer, Colonic Neoplasms, Colorectal Neoplasms, ER Positive Breast Cancer, Estrogen Receptor Positive Tumor, HER-2 Protein Overexpression, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, HER2 Mutation-Related Tumors, HER2-negative Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, HR Positive, Hormone Receptor Negative Breast Carcinoma, Hormone Receptor-positive Breast Cancer, Metastatic, Metastatic Breast Cancer, Metastatic Cancer, Minimal Residual Disease, Neoplasm, Residual, PR-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Rectal Cancer, Rectal Neoplasms, Solid Carcinoma, Solid Tumor, Solid Tumor, Adult, Triple Negative Breast Cancer, ctDNA Monitoring
- Interventions
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, TTX-MC138, Tucatinib, Zanidatamab
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
- Conditions
- Asthma
- Interventions
- ELLIPTA, FF/UMEC/VI, FF/VI
- Device · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 23 more
- Conditions
- Metastatic Breast Cancer, Ovarian Cancer
- Interventions
- Not listed
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota
- Conditions
- Endometrial Cancer
- Interventions
- Matching Placebo for selinexor, Selinexor
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Placebo cagrilintide, Placebo semaglutide, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more
- Conditions
- COPD
- Interventions
- Ensifentrine, Placebo
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- Moderate Aortic Valve Stenosis
- Interventions
- Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2034
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
- Conditions
- Bone Loss
- Interventions
- E-PRF only, E-PRF/ACS/rhBMP-2, E-PRF/rhBMP-2 (similar ratios), rhBMP-2/E-PRF
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- Interspinous Process Decompression, MILD
- Device
- Lead sponsor
- Stryker Instruments
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2382
- States / cities
- Athens, Alabama • Bay Minette, Alabama • Birmingham, Alabama + 1285 more
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more